Status:
UNKNOWN
Botulinum Toxin for Chronic Neuropathic Pain
Lead Sponsor:
Region Zealand
Conditions:
Neuralgia
Chronic Pain
Eligibility:
All Genders
18+ years
Brief Summary
Treatment of peripheral neuropathic pain with Botulinum Toxin (BoNT) has showed promising results since the first study was released in 2001. Further research, however, is needed in order to strengthe...
Detailed Description
Background: There are eight randomized controlled trials investigating the effectiveness of BoNT for peripheral neuropathic pain. The indications in the studies include diabetic neuropathy, post-herp...
Eligibility Criteria
Inclusion
- Condition of neuropathic pain verified by paraclinical examination or supported by underlying diseases (e.g., diabetes or herpes zoster).
- The condition is characterized by allodynia, hyperalgesia, and/or neuralgiform symptoms such as burning and stabbing pain.
- The affected area can be identified through objective examination with detection of disturbances in touch using cotton swabs, pin-prick, and/or vibration
Exclusion
- Mixed etiology of pain not solely attributable to neuropathy (e.g., fibromyalgia and neuropathy or nociceptive pain and neuropathy).
- Contraindication to BoNT treatment (allergy to the toxin).
- Pregnancy.
- Diseases where BoNT treatment is contraindicated, such as motor neuron diseases and muscular dystrophy.
- Severe psychiatric disorder.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06036043
Start Date
August 1 2023
End Date
December 30 2024
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of regions Zealand
Køge, Denmark, 4600